arrow
I

Ivan Špıčka

first faculty of medicine
H指数:46
被引数:1.5万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Efficacy and safety of isatuximab subcutaneous plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma: results of the Phase 2 study IZALCO

伊沙佐米单抗皮下注射联合卡非佐米和地塞米松治疗复发/难治性多发性骨髓瘤的疗效与安全性:IZALCO II期研究结果

2025-12-270
OAAI
Patient-reported outcomes with belantamab mafodotin, pomalidomide, and dexamethasone versus bortezomib, pomalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-8): a phase 3, open-label, randomised controlled trial

患者报告的结果:比较belantamab mafodotin联合pomalidomide和地塞米松与 bortezomib联合pomalidomide和地塞米松在复发或难治性多发性骨髓瘤患者中的疗效(DREAMM-8):一项III期、开放标签、随机对照试验

2025-11-030
PRE
Treatment Patterns and Outcomes in Over 2,200 newly diagnosed multiple myeloma patients: Supporting bortezomib-lenalidomide-dexamethasone as a preferred regimen in the absence of anti-CD38 antibodies

超过2,200例新诊断多发性骨髓瘤患者的治疗模式与结局:支持在无抗-CD38抗体的情况下将硼替佐米-来那度胺-地塞米松作为优选方案

2025-11-020
PRE
Modification of Belantamab Mafodotin Dosing to Balance Efficacy and Tolerability in the DREAMM-7 and DREAMM-8 Trials

在DREAMM-7和DREAMM-8试验中调整Belantamab Mafodotin给药剂量以平衡疗效和耐受性

2025-08-070
OAAI
Belantamab Mafodotin Plus Pomalidomide and Dexamethasone Vs Pomalidomide Plus Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: A Subset Analysis in Patients Who Have Received 1 Prior Line of Therapy Including Lenalidomide

贝兰他单抗马福替尼联合泊马利度胺和地塞米松与泊马利度胺联合硼替佐米和地塞米松治疗复发/难治性多发性骨髓瘤:在接受过包含来那度胺的1线先前治疗的患者亚组分析

BLOOD
IF23.1
2024-11-053
PRE
Isatuximab plus carfilzomib-dexamethasone versus carfilzomib-dexamethasone in patients with relapsed multiple myeloma (IKEMA): overall survival analysis of a phase 3, randomised, controlled trial
2024-10-015
PRE
Health-related quality of life in relapsed/refractory multiple myeloma treated with melflufen and dexamethasone: analyses from the phase III OCEAN study
2024-02-290
OAAI
Isatuximab-pomalidomide-dexamethasone versus pomalidomide-dexamethasone in patients with relapsed and refractory multiple myeloma: final overall survival analysis

Isatuximab-泊马度胺-地塞米松与泊马度胺-地塞米松在复发和难治性多发性骨髓瘤患者中的比较: 最终总生存分析

2024-02-017
OAAI
Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study (vol 13, 152, 2023)
2023-09-271
OAAI
Clinical characteristics and outcomes in risk-stratified patients with smoldering multiple myeloma: data from the Czech Republic Registry of Monoclonal Gammopathies
2023-09-271
OAAI
Efficacy and safety of melflufen plus daratumumab and dexamethasone in relapsed/refractory multiple myeloma: results from the randomized, open-label, phase III LIGHTHOUSE study
2023-08-318
OAAI
Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study
2023-05-0944
OAAI
Daratumumab with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma patients - real world evidence analysis

Daratumumab联合来那度胺和地塞米松治疗复发或难治性多发性骨髓瘤-真实世界证据分析

2023-04-243
OAAI
Personalised progression prediction in patients with monoclonal gammopathy of undetermined significance or smouldering multiple myeloma (PANGEA): a retrospective, multicohort study

具有不确定意义的单克隆丙种球蛋白病或闷烧性多发性骨髓瘤 (PANGEA) 患者的个性化进展预测: 一项回顾性,多职业研究

2023-03-0119
OAAI